COMPANY PROFILE // THE 014 REPORT
Atea Pharmaceuticals, Inc.
AVIR (Nasdaq)
Assembled from 3 government sources in 0.1 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
No flag from the records checked. 26 of 26 lists and sources checked came back clear (panel below).
✓ SEC filings✓ State registrationpossible match✗ LEI✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no website, no lobbying registration on record.
Atea Pharmaceuticals, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in MA, based in Boston, MA; listed as AVIR (Nasdaq).[source] It has filed 41 documents with the SEC in the last 12 months; the latest is Form 4, filed 2026-11-18.[source] Its largest institutional holders on 13F filings are FMR LLC, BlackRock, Inc., BML Capital Management, LLC (as of 2026-06-30).[source] Every list and source checked for this page came back clear (26 of 26), dated in the checks panel.[source]
- red0
- amber0
- info0
- FMR LLC$55.8M
- BlackRock, Inc.$40.5M
- BML Capital Management, LLC$32.3M
- TANG CAPITAL MANAGEMENT LLC$22.4M
- VANGUARD CAPITAL MANAGEMENT LLC$13.8M
- Bain Capital Life Sciences Investors, LLC$9.7M
- GEODE CAPITAL MANAGEMENT, LLC$9.1M
- STATE STREET CORP$7.7M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Corcoran Andrea · See Remarks (Officer) · latest Form 4 2026-03-13 · filing · LinkedIn search
- Foster Wayne · EVP, Chief Accounting Officer (Officer) · latest Form 4 2026-02-03 · filing · LinkedIn search
- Hammond Janet MJ · Chief Development Officer (Officer) · latest Form 4 2026-02-03 · filing · LinkedIn search
- Horga Maria Arantxa · Chief Medical Officer (Officer) · latest Form 4 2026-02-03 · filing · LinkedIn search
- Sommadossi Jean-Pierre · President, CEO, and Chairman (Director,Officer) · latest Form 4 2026-02-03 · filing · LinkedIn search
- Vavricka John · Chief Commercial Officer (Officer) · latest Form 4 2026-02-03 · filing · LinkedIn search
- Adams Jerome M. · Director · latest Form 4 2025-06-24 · filing · LinkedIn search
- BERGER FRANKLIN M · Director · latest Form 4 2025-06-24 · filing · LinkedIn search
- Berman Howard · Director · latest Form 4 2025-06-24 · filing · LinkedIn search
- Duncan Barbara Gayle · Director · latest Form 4 2025-06-24 · filing · LinkedIn search
- Lucidi Bruno · Director · latest Form 4 2025-06-24 · filing · LinkedIn search
- Murphy Polly A. · Director · latest Form 4 2025-06-24 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001593899 | source |
| EIN | 46-0574869 | source |
| Connecticut business ID | 3530984 | record |
| Business address (SEC) | 225 FRANKLIN STREET, BOSTON, MA, 02110 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
At the same address (3)
- NATIONAL MENTORING PARTNERSHIP INCORPORATED · IRS-registered organization
- LOTUS FLOWER FOUNDATION · IRS-registered organization
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Coya Therapeutics, Inc. · Berman Howard
- HALOZYME THERAPEUTICS, INC. · Duncan Barbara Gayle
- Ovid Therapeutics Inc. · Duncan Barbara Gayle
- Celcuity Inc. · Murphy Polly A.
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-18 filing 144 · SEC EDGAR
- 2026-11-17 filing 144 · SEC EDGAR
- 2026-11-17 filing 144 · SEC EDGAR
- 2026-11-16 filing 144 · SEC EDGAR
- 2026-11-09 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-09 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-11-09 filing 8-K items 1.01,2.03,9.01 · SEC EDGAR
- 2026-08-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-12 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-06-22 filing 8-K items 5.07 · SEC EDGAR
- 2026-05-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-12 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-27 filing DEFA14A · SEC EDGAR
- 2026-04-27 filing Proxy statement · SEC EDGAR
- 2026-03-05 filing Annual report (10-K) · SEC EDGAR
- 2026-03-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-02-03 insider First Form 3/4/5 on record for Corcoran Andrea (See Remarks) · SEC Forms 3/4/5
- 2026-02-03 insider First Form 3/4/5 on record for Foster Wayne (EVP, Chief Accounting Officer) · SEC Forms 3/4/5
- 2026-02-03 insider First Form 3/4/5 on record for Hammond Janet MJ (Chief Development Officer) · SEC Forms 3/4/5
- 2026-02-03 insider First Form 3/4/5 on record for Horga Maria Arantxa (Chief Medical Officer) · SEC Forms 3/4/5
- 2026-02-03 insider First Form 3/4/5 on record for Sommadossi Jean-Pierre (President, CEO, and Chairman) · SEC Forms 3/4/5
- 2026-02-03 insider First Form 3/4/5 on record for Vavricka John (Chief Commercial Officer) · SEC Forms 3/4/5
- 2026-01-08 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2025-11-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2025-11-12 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2025-08-07 filing S-8 · SEC EDGAR
- 2025-08-07 filing Quarterly report (10-Q) · SEC EDGAR
- 2025-08-07 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2025-06-24 insider First Form 3/4/5 on record for Adams Jerome M. (Director) · SEC Forms 3/4/5
- 2025-06-24 insider First Form 3/4/5 on record for BERGER FRANKLIN M (Director) · SEC Forms 3/4/5
132 earlier entries
- 2025-06-24 insider First Form 3/4/5 on record for Berman Howard (Director)
- 2025-06-24 insider First Form 3/4/5 on record for Duncan Barbara Gayle (Director)
- 2025-06-24 insider First Form 3/4/5 on record for Lucidi Bruno (Director)
- 2025-06-24 insider First Form 3/4/5 on record for Murphy Polly A. (Director)
- 2025-06-24 insider First Form 3/4/5 on record for Polsky Bruce (Director)
- 2025-06-20 filing 8-K items 5.07
- 2025-05-12 filing Quarterly report (10-Q)
- 2025-05-12 filing 8-K items 2.02,9.01
- 2025-04-29 filing Proxy statement
- 2025-04-17 filing SCHEDULE 13D/A
- 2025-04-17 officer change 8-K items 1.01,2.02,5.02,7.01,9.01
- 2025-04-03 filing DEFA14A
- 2025-04-01 filing DEFA14A
- 2025-04-01 filing 8-K items 8.01
- 2025-03-26 filing DEFA14A
- 2025-03-26 filing DFAN14A
- 2025-03-24 filing DEFA14A
- 2025-03-24 filing 8-K items 8.01,9.01
- 2025-03-21 filing SCHEDULE 13D/A
- 2025-03-06 filing Annual report (10-K)
- 2025-03-06 filing 8-K items 2.02,9.01
- 2025-03-04 filing SCHEDULE 13D
- 2025-02-24 officer change 8-K items 5.02
- 2025-01-14 filing 8-K items 2.02,9.01
- 2024-12-16 filing SCHEDULE 13D
- 2024-12-10 filing 144
- 2024-11-19 filing EFFECT
- 2024-11-15 filing CORRESP
- 2024-11-14 filing UPLOAD
- 2024-11-07 filing S-3
- 2024-11-07 filing Quarterly report (10-Q)
- 2024-11-07 filing 8-K items 2.02,9.01
- 2024-09-19 filing 144
- 2024-09-18 filing 144
- 2024-09-17 filing 144
- 2024-08-07 filing Quarterly report (10-Q)
- 2024-08-07 filing 8-K items 2.02,9.01
- 2024-06-21 filing 8-K items 5.07
- 2024-06-20 filing 144
- 2024-06-05 filing 144
- 2024-06-04 filing DEFA14A
- 2024-05-14 filing Quarterly report (10-Q)
- 2024-05-14 filing 8-K items 2.02,9.01
- 2024-04-26 filing DEFA14A
- 2024-04-26 filing Proxy statement
- 2024-02-28 filing Annual report (10-K)
- 2024-02-28 filing 8-K items 2.02,9.01
- 2024-02-01 filing 144
- 2024-02-01 filing 144
- 2024-02-01 filing 144
- 2024-02-01 filing 144
- 2024-02-01 filing 144
- 2024-02-01 filing 144
- 2023-11-28 filing SC 13D/A
- 2023-11-08 filing Quarterly report (10-Q)
- 2023-11-08 filing 8-K items 2.02,9.01
- 2023-08-08 filing Quarterly report (10-Q)
- 2023-08-08 filing 8-K items 2.02,9.01
- 2023-06-21 filing 8-K items 5.03,5.07,9.01
- 2023-06-12 filing DEFA14A
- 2023-05-25 filing DEFA14A
- 2023-05-22 filing SC 13D
- 2023-05-08 filing Quarterly report (10-Q)
- 2023-05-08 filing 8-K items 2.02,9.01
- 2023-04-28 filing ARS
- 2023-04-28 filing DEFA14A
- 2023-04-28 filing Proxy statement
- 2023-02-28 filing Annual report (10-K)
- 2023-02-28 filing 8-K items 2.02,9.01
- 2022-11-07 filing Quarterly report (10-Q)
- 2022-11-07 filing 8-K items 2.02,9.01
- 2022-08-08 filing Quarterly report (10-Q)
- 2022-08-08 filing 8-K items 2.02,9.01
- 2022-06-21 filing 8-K items 5.07
- 2022-05-12 filing EFFECT
- 2022-05-10 filing POS AM
- 2022-05-10 filing Quarterly report (10-Q)
- 2022-05-10 filing 8-K items 2.02,9.01
- 2022-04-29 filing DEFA14A
- 2022-04-29 filing Proxy statement
- 2022-03-01 filing POS AM
- 2022-02-28 filing Annual report (10-K)
- 2022-02-28 filing POSASR
- 2022-02-28 filing 8-K items 2.02,9.01
- 2022-01-10 filing 8-K items 7.01,9.01
- 2021-11-26 filing 8-K items 7.01
- 2021-11-24 filing S-3ASR
- 2021-11-16 filing 8-K items 1.02
- 2021-11-12 filing Quarterly report (10-Q)
- 2021-11-12 filing 8-K items 2.02,9.01
- 2021-09-24 filing SC 13D/A
- 2021-09-03 filing SC 13D/A
- 2021-08-12 filing Quarterly report (10-Q)
- 2021-08-12 filing 8-K items 2.02,9.01
- 2021-07-23 filing 8-K items 1.01,2.03,9.01
- 2021-06-21 filing 8-K items 5.07
- 2021-05-20 officer change 8-K items 5.02,9.01
- 2021-05-20 filing DEFA14A
- 2021-05-13 filing Quarterly report (10-Q)
- 2021-05-13 filing 8-K items 2.02,9.01
- 2021-04-29 filing DEFA14A
- 2021-04-29 filing Proxy statement
- 2021-04-19 officer change 8-K items 5.02
- 2021-03-30 filing Annual report (10-K)
- 2020-12-10 filing Quarterly report (10-Q)
- 2020-11-12 filing SC 13D
- 2020-11-05 filing 8-K items 5.03,9.01
- 2020-10-30 filing S-8
- 2020-10-30 filing 424B4
- 2020-10-29 filing EFFECT
- 2020-10-29 filing S-1MEF
- 2020-10-29 filing CORRESP
- 2020-10-28 filing CERT
- 2020-10-27 filing SEC STAFF LETTER
- 2020-10-27 filing CORRESP
- 2020-10-27 filing CORRESP
- 2020-10-27 filing UPLOAD
- 2020-10-26 filing S-1/A
- 2020-10-26 filing 8-A12B
- 2020-10-23 filing SEC STAFF LETTER
- 2020-10-23 filing S-1/A
- 2020-10-09 filing Registration (S-1)
- 2020-08-07 filing DRSLTR
- 2020-08-07 filing DRS/A
- 2020-07-16 filing UPLOAD
- 2020-06-19 filing DRS
- 2020-05-29 filing D
- 2018-07-16 filing D
- 2016-09-13 filing D
- 2014-09-17 filing D/A
- 2014-05-21 filing D/A
- 2013-12-11 filing D
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-09 (within 30 days) 10-Q filed
- 2026-11-09 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-11-09 (within 30 days) 8-K filed: Item 1.01 material agreement; Item 2.03 new financial obligation; Item 9.01 exhibits
- 2026-09-30 (older) Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-08-12 (older) 10-Q filed
- 2026-08-12 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-06-22 (older) 8-K filed: Item 5.07 shareholder vote
- 2026-05-12 (older) 10-Q filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-19; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:AVIR The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
2 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1593899 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | AVIR / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 460574869 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001593899 | SEC EDGAR / IRS |
| CUSIP | 04683R106 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001593899 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$158,349,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-19 22:39 UTC | Report an error |
| Total assets (at 2025-12-31) | $315,218,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-19 22:39 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $275,434,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-19 22:39 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $95,713,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-19 22:39 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 22:39 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 22:39 UTC | Report an error |
| State of incorporation | MA | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 22:39 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 22:39 UTC | Report an error |
| Business address | 225 FRANKLIN STREET, SUITE 2100, BOSTON, MA, 02110 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 22:39 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-19 22:39 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$132,031,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-19 22:39 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $843,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-19 22:39 UTC | Report an error |
| Form D total offering amount (D filed 2020-05-29) | $214,999,608 | 2020-05-29 | D | as filed | 2026-11-19 22:39 UTC | Report an error |
| Form D total amount sold (D filed 2020-05-29) | $107,499,941 | 2020-05-29 | D | as filed | 2026-11-19 22:39 UTC | Report an error |
| Form D industry group | Biotechnology | 2020-05-29 | D | as filed | 2026-11-19 22:39 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2020-05-29 | D | as filed | 2026-11-19 22:39 UTC | Report an error |
| Form D date of first sale | 2020-05-19 | 2020-05-29 | D | as filed | 2026-11-19 22:39 UTC | Report an error |
| Plan (pension, plan no. 001) | ATEA PHARMACEUTICALS 401(K) RETIREMENT SAVINGS PLAN: 66 participants | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-19 22:39 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001193125-26-453807
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$32,162,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0001193125-26-453807 | 2026-11-19 22:39 UTC | Report an error |
| Cash and cash equivalents | $97,922,000 | at 2026-09-30 | 10-Q | 2026-11-09 | 0001193125-26-453807 | 2026-11-19 22:39 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-09 Filing 10-Q filed
- 2026-11-09 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-11-09 Filing 8-K filed: Item 1.01 material agreement; Item 2.03 new financial obligation; Item 9.01 exhibits
- 2026-09-30 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-08-12 Filing 10-Q filed
- 2026-08-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-06-22 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-12 Filing 10-Q filed
- 2026-05-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-27 Filing DEFA14A filed
- 2026-04-27 Filing DEF 14A filed
- 2026-03-05 Filing 10-K filed
- 2026-03-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-01-08 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-11-12 Filing 10-Q filed
- 2025-11-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-08-07 Filing S-8 filed
- 2025-08-07 Filing 10-Q filed
- 2025-08-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-06-20 Filing 8-K filed: Item 5.07 shareholder vote
- 2025-05-12 Filing 10-Q filed
- 2025-05-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-04-29 Filing DEF 14A filed
- 2025-04-17 Filing 8-K filed: Item 1.01 material agreement; Item 2.02 results of operations; Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2025-04-03 Filing DEFA14A filed
2 earlier entries
- 2025-04-01 Filing DEFA14A filed
- 2021-04-15 Record plan effective date: ATEA PHARMACEUTICALS 401(K) RETIREMENT SAVINGS PLAN
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | $55,818,898 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 2 | BlackRock, Inc. | $40,548,360 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 3 | BML Capital Management, LLC | $32,328,335 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 4 | TANG CAPITAL MANAGEMENT LLC | $22,388,355 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | $13,786,608 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 6 | Bain Capital Life Sciences Investors, LLC | $9,651,721 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | $9,108,898 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 8 | STATE STREET CORP | $7,683,655 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 9 | TWO SIGMA INVESTMENTS, LP | $7,006,141 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
| 10 | DIMENSIONAL FUND ADVISORS LP | $6,042,497 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:39 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
2 state and city records carry this company's exact name, from 2 sources. Possible matches only.
Connecticut business registrations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchAtea Pharmaceuticals, Inc. · exact legal name · sx:ctsos:3530984 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchAtea Pharmaceuticals, Inc. · exact legal name · sx:ctgov:he218e673de721dff Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1593899.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001593899. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.